To identify novel therapeutic approaches, researchers performed CRISPR/Cas9 knockout screens and discovered TGFβ activated kinase (TAK1) as a selective survival factor in a significant fraction of glioma stem cells.
[Cell Death & Disease]
Home Newsletters Cancer Stem Cell News TAK1 Inhibition Leads to RIPK1-Dependent Apoptosis in Immune-Activated Cancers
